The U.S. Court of Appeals for the Fifth Circuit has overturned several FDA marketing denial orders for e-cigarettes due to procedural errors. The court ruled that the agency acted unlawfully by imposing a strict comparative efficacy standard on manufacturers without public notice and comment.
The U.S. Fifth Circuit Court of Appeals has issued another ruling against the Food and Drug Administration (FDA). The court invalidated the agency’s marketing denial orders for several vape manufacturers and remanded the applications for further review.
According to the court’s reasoning, the FDA committed a procedural error by imposing a binding comparative efficacy requirement on manufacturers regarding smoking cessation. Under U.S. administrative law, this requirement should have been established through a public rulemaking process; therefore, the failure to do so rendered the decisions unlawful.
Although the ruling does not automatically grant marketing authorization, it provides a new opportunity for the affected manufacturers. Due to the uncertainty in federal regulation, several states—such as Pennsylvania—have taken their own measures, tying the sale of unauthorized vape products to mandatory registration or local bans.
In Brief
- The U.S. 5th Circuit Court of Appeals overturned the FDA’s denial orders due to procedural errors.
- The agency applied a significant rule regarding the efficacy of e-cigarettes for smoking cessation without public consultation.
- The applications will be returned to the FDA, giving the manufacturers’ products another chance for a proper review.
- Due to legal uncertainty at the federal level, an increasing number of states are introducing their own restrictions and registries.
Source: Vapoteurs (vapoteurs.net)
This summary was generated by artificial intelligence based on the original article.